HolderBook

Abingworth LLP

Reported holdings as of Q4 2022, from 17 quarterly filings.

This filer last reported in Q4 2022; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1397144
Reported value
$306.9M
Positions
19
Top 10 weight
96.9%
Filed
2023-02-10
Days after quarter end
41

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
VAXCYTE INCPCVX$96.8M2,019,05731.54%-2.66pp11q-51.6%-$103.1M
VERONA PHARMA PLCVRNA$64.2M2,457,50020.92%+12.34pp17qHELD
VERA THERAPEUTICS INCVERA$57.3M2,960,23118.66%-2.91pp7qHELD
HILLEVAX INCHLVX$30.8M1,838,48610.02%-0.71pp3qHELD
ADICET BIO INCACET$18.9M2,115,3856.16%-4.10pp8qHELD
PHATHOM PHARMACEUTICALS INCPHAT$16.1M1,435,1065.25%-0.19pp13qHELD
RENEO PHARMACEUTICALS INCRPHM$4.8M2,073,9571.57%-0.80pp7qHELD
SIENTRA INCSIENXXXX$3.4M1,673,5891.11%+0.74pp17qHELD
JASPER THERAPEUTICS INCJSPRXXXX$2.7M5,628,5580.89%-0.63pp6qHELD
SOLENO THERAPEUTICS INCSLNO$2.4M1,201,5060.78%+0.09pp2qHELD
NUCANA PLCNCNA$2.2M3,333,3330.72%-0.45pp10qHELD
EFFECTOR THERAPEUTICS INCEFTR$2.1M4,822,1140.67%-0.26pp6qHELD
SPRUCE BIOSCIENCES INCSPRB$2.0M1,792,5180.64%-0.21pp2qHELD
PARATEK PHARMACEUTICALS INCPRTK$1.9M1,041,1310.63%-0.28pp17qHELD
CYMABAY THERAPEUTICS INCCBAY$821.6K131,0360.27%+0.11pp17qHELD
EXICURE INCXCUR$323.9K281,6360.11%-0.04pp2qHELD
AEGLEA BIOTHERAPEUTICS INCAGLE$108.2K240,5000.04%-0.01pp16qHELD
MOLECULAR TEMPLATES INCMTEM$66.0K200,0000.02%-0.03pp13qHELD
OBSEVA SAOBSVF$12.8K87,9990.00%flat17qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 63.8%Not classified 36.2%
 
SectorValueShare
Biotech & Pharma$193.6M63.8%
Not classified$109.9M36.2%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q4 2022$306.9M19001096.9%41
Q3 2022$292.5M19300596.8%41
Q2 2022$312.4M21102095.7%46
Q1 2022$352.5M20030095.2%46
Q4 2021$412.7M20010093.0%47
Q3 2021$440.7M20221189.5%46
Q2 2021$323.5M19200090.0%47
Q1 2021$289.6M17200095.0%47
Q4 2020$292.3M15101398.4%60
Q3 2020$467.5M17212197.6%47
Q2 2020$357.7M16210297.5%45
Q1 2020$150.6M16110196.4%44
Q4 2019$206.9M16231098.4%45
Q3 2019$158.2M14103199.2%45
Q2 2019$260.8M14103199.2%45
Q1 2019$111.7M14322597.0%45
Q4 2018$110.1M16000094.3%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.